Telmisartan Teva Pharma

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

Telmisartan

Available from:

Teva B.V.

ATC code:

C09CA07

INN (International Name):

telmisartan

Therapeutic group:

Aġenti li jaġixxu fuq is-sistema renin-angiotensin

Therapeutic area:

Pressjoni għolja

Therapeutic indications:

Trattament ta 'pressjoni għolja essenzjali fl-adulti.

Product summary:

Revision: 10

Authorization status:

Awtorizzat

Authorization date:

2011-10-03

Patient Information leaflet

                                45
B. FULJETT TA’ TAGĦRIF
46
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-UTENT
Telmisartan Teva Pharma 20 mg pilloli
Telmisartan
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TIEĦU DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK.
-
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
-
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib jew lill-ispiżjar
tiegħek.
-
Din il-mediċina ġiet mogħtija lilek biss. M’għandekx tgħaddiha
lil persuni oħra. Tista’
tagħmlilhom il-ħsara, anke jekk għandhom l-istess sinjali ta’
mard bħal tiegħek.
-
Jekk ikollok xi effett sekondarju kellem lit-tabib jew lill-ispiżjar
tiegħek. Dan jinkludi xi effett
sekondarju possibbli li mhuwiex elenkat f’dan il-fuljett.
F’DAN IL-FULJETT
1.
X’inhu Telmisartan Teva Pharma u għalxiex jintuża
2.
X’għandek tkun taf qabel ma tieħu Telmisartan Teva Pharma
3.
Kif għandek tieħu Telmisartan Teva Pharma
4.
Effetti sekondarji possibbli
5.
Kif taħżen Telmisartan Teva Pharma
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU TELMISARTAN TEVA PHARMA U GĦALXIEX JINTUŻA
Telmisartan Teva Pharma jappartjeni għal klassi ta’ mediċini
magħrufa bħala antagonisti tar-riċetturi
ta’ angiotensin II. Angiotensin-II hija sustanza li tinsab
fil-ġisem li tikkawża l-vini u l-arterji tad-
demm biex jiddjiequ, u b’hekk l-pressjoni tad-demm tiegħek togħla.
Telmisartan Teva Pharma
jimblokka dan l-effett ta’ angiotensin II, sabiex il-vażi tad-demm
tiegħek jistrieħu, u l-pressjoni tad-
demm tiegħek titbaxxa.
Telmisartan Teva Pharma jintuża għall-kura ta’ pressjoni tad-demm
għolja (ipertensjoni essenzjali)
f’pazjenti adulti. ‘Essenzjali’ tfisser li l-pressjoni tad-demm
mhix ikkawżata minn xi kundizzjoni oħra.
Il-pressjoni tad-demm għolja, jekk ma tkunx ikkurata, tista’
tagħmel il-ħsara lil diversi organi, li tista’
twassal għal attakki tal-qalb, insuffiċjenza tal-qalb jew
tal-kliewi, attakki ta’ puplesija jew li tagħma.
Ġeneralment ma jkunx hemm sintomi ta’ pressj
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM IL-PRODOTT MEDIĊINALI
Telmisartan Teva Pharma 20 mg pilloli
Telmisartan Teva Pharma 40 mg pilloli
Telmisartan Teva Pharma 80 mg pilloli
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
_ _
Telmisartan Teva Pharma 20 mg pilloli
Kull pillola fiha 20 mg telmisartan
Telmisartan Teva Pharma 40 mg pilloli
Kull pillola fiha 40 mg telmisartan.
Telmisartan Teva Pharma 80 mg pilloli
Kull pillola fiha 80 mg telmisartan.
Eċċipjenti b’effett magħruf
Telmisartan Teva Pharma 20 mg pilloli
Kull pillola fiha 21.4 mg sorbitol (E420)
Telmisartan Teva Pharma 40 mg pilloli
Kull pillola fiha 42.8 mg sorbitol (E420)
Telmisartan Teva Pharma 80 mg pilloli
Kull pillola fiha 85.6 mg sorbitol (E420)
Għal-lista sħiħa ta' eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola
Telmisartan Teva Pharma 20 mg pilloli
Pilloli bajda għal ofwajt, f’għamla ovali; naħa waħda
tal-pillola hemm intaljat fuqha l-kodiċi “93”.
Fuq naħa oħra hemm intaljat il-kodiċi
”7458”.
Telmisartan Teva Pharma 40 mg pilloli
Pillola bajda sa abjad maħmuġ, b’għamla ovali; naħa waħda
tal-pillola mnaqqxa bin-numru "93". In-
naħa l-oħra tal-pillola mnaqqxa bin-numru "7459".
Telmisartan Teva Pharma 80 mg pilloli
Pillola bajda sa abjad maħmuġ, b’għamla ovali; naħa waħda
tal-pillola mnaqqxa bin-numru "93". In-
naħa l-oħra tal-pillola mnaqqxa bin-numru "7460”.
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
Pressjoni għolja
Il-kura ta’ pressjoni tad-demm għolja essenzjali.
3
Prevenzjoni kardjovaskulari
Tnaqqis ta’ morbożità kardjovaskulari f’adulti bi:
•
mard kardjovaskulari aterotrombotiku sintomatiku (storja medika ta’
mard koronarju tal-qalb,
puplesija, jew mard arterjali periferali) jew
•
dijabete mellitus ta’ tip 2 bi ħsara dokumentata tal-organu
fil-mira
4.2
POŻOLOĠIJA U METODU TA’ KIF GĦANDU JINGĦATA
Pożoloġija
Kura ta’ pressjoni tad-demm għolja essenzjali
Id-doża effettiva normalment hi ta’ 40 mg darba kuljum. Xi pazjenti
jist
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 26-10-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 26-10-2021
Public Assessment Report Public Assessment Report Bulgarian 19-06-2015
Patient Information leaflet Patient Information leaflet Spanish 26-10-2021
Public Assessment Report Public Assessment Report Spanish 19-06-2015
Patient Information leaflet Patient Information leaflet Czech 26-10-2021
Public Assessment Report Public Assessment Report Czech 19-06-2015
Patient Information leaflet Patient Information leaflet Danish 26-10-2021
Public Assessment Report Public Assessment Report Danish 19-06-2015
Patient Information leaflet Patient Information leaflet German 26-10-2021
Public Assessment Report Public Assessment Report German 19-06-2015
Patient Information leaflet Patient Information leaflet Estonian 26-10-2021
Public Assessment Report Public Assessment Report Estonian 19-06-2015
Patient Information leaflet Patient Information leaflet Greek 26-10-2021
Public Assessment Report Public Assessment Report Greek 19-06-2015
Patient Information leaflet Patient Information leaflet English 26-10-2021
Public Assessment Report Public Assessment Report English 19-06-2015
Patient Information leaflet Patient Information leaflet French 26-10-2021
Public Assessment Report Public Assessment Report French 19-06-2015
Patient Information leaflet Patient Information leaflet Italian 26-10-2021
Public Assessment Report Public Assessment Report Italian 19-06-2015
Patient Information leaflet Patient Information leaflet Latvian 26-10-2021
Public Assessment Report Public Assessment Report Latvian 19-06-2015
Patient Information leaflet Patient Information leaflet Lithuanian 26-10-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 26-10-2021
Public Assessment Report Public Assessment Report Lithuanian 19-06-2015
Patient Information leaflet Patient Information leaflet Hungarian 26-10-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 26-10-2021
Public Assessment Report Public Assessment Report Hungarian 19-06-2015
Patient Information leaflet Patient Information leaflet Dutch 26-10-2021
Public Assessment Report Public Assessment Report Dutch 19-06-2015
Patient Information leaflet Patient Information leaflet Polish 26-10-2021
Public Assessment Report Public Assessment Report Polish 19-06-2015
Patient Information leaflet Patient Information leaflet Portuguese 26-10-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 26-10-2021
Public Assessment Report Public Assessment Report Portuguese 19-06-2015
Patient Information leaflet Patient Information leaflet Romanian 26-10-2021
Public Assessment Report Public Assessment Report Romanian 19-06-2015
Patient Information leaflet Patient Information leaflet Slovak 26-10-2021
Public Assessment Report Public Assessment Report Slovak 19-06-2015
Patient Information leaflet Patient Information leaflet Slovenian 26-10-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 26-10-2021
Public Assessment Report Public Assessment Report Slovenian 19-06-2015
Patient Information leaflet Patient Information leaflet Finnish 26-10-2021
Public Assessment Report Public Assessment Report Finnish 19-06-2015
Patient Information leaflet Patient Information leaflet Swedish 26-10-2021
Public Assessment Report Public Assessment Report Swedish 19-06-2015
Patient Information leaflet Patient Information leaflet Norwegian 26-10-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 26-10-2021
Patient Information leaflet Patient Information leaflet Icelandic 26-10-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 26-10-2021
Patient Information leaflet Patient Information leaflet Croatian 26-10-2021
Public Assessment Report Public Assessment Report Croatian 19-06-2015

Search alerts related to this product